Phosphodiesterase activity in intrapulmonary arteries and veins of perinatal lambs. 1998

A C Okogbule-Wonodi, and B O Ibe, and B W Yue, and S Hsu, and J U Raj
UCLA School of Medicine, Harbor-UCLA Medical Center, Torrance, California, 90509, USA.

The transition from fetal to newborn life is marked by a reduction in pulmonary vascular tone mediated by the intracellular second messengers, cGMP and cAMP. We have compared the rates of phosphodiesterase (PDE)-catalyzed hydrolysis of cGMP and cAMP in intrapulmonary vessels of fetal (146 +/- 2 days gestation) and newborn (3-7-day-old) lambs, each n = 6. Lung vessels of second to sixth generations were dissected and cytosol was prepared by differential centrifugation. PDE activity in cytosol was determined by radiometric assay of the hydrolysis of exogenous nucleotides at 30 degrees C for 10 min. Rates of hydrolysis (pmol/min/mg protein) of cGMP were 225 +/- 38 in fetal arteries and different from 151 +/- 7 in veins. In newborn vessels, the rates were 155 +/- 49 and 63 +/- 13 in arteries and veins, respectively. Rates of cAMP hydrolysis by the fetus were 80 +/- 11 in arteries and 45 +/- 16 veins. In newborn lambs the rates were 69 +/- 10 in arteries and different from 18 +/- 4 in veins. Inhibition of PDE activity by zaprinast, a cGMP-specific PDE inhibitor, and rolipram, a cAMP-specific PDE inhibitor, was more in veins of fetal and newborn lambs. Our data show that rates of hydrolysis of the cyclic nucleotides were faster in fetal vessels than in the newborn. We speculate that this would result in a greater accumulation of the cyclic nucleotides in newborn vessels, particularly the veins, and therefore endow the veins with less vascular tone.

UI MeSH Term Description Entries
D010726 Phosphodiesterase Inhibitors Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. Phosphodiesterase Antagonists,Phosphodiesterase Inhibitor,Phosphoric Diester Hydrolase Inhibitors,Antiphosphodiesterases,Inhibitor, Phosphodiesterase
D010727 Phosphoric Diester Hydrolases A class of enzymes that catalyze the hydrolysis of one of the two ester bonds in a phosphodiester compound. EC 3.1.4. Phosphodiesterase,Phosphodiesterases,Hydrolases, Phosphoric Diester
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011651 Pulmonary Artery The short wide vessel arising from the conus arteriosus of the right ventricle and conveying unaerated blood to the lungs. Arteries, Pulmonary,Artery, Pulmonary,Pulmonary Arteries
D011667 Pulmonary Veins The veins that return the oxygenated blood from the lungs to the left atrium of the heart. Pulmonary Vein,Vein, Pulmonary,Veins, Pulmonary
D011688 Purinones Oxopurines
D011760 Pyrrolidinones A group of compounds that are derivatives of oxo-pyrrolidines. A member of this group is 2-oxo pyrrolidine, which is an intermediate in the manufacture of polyvinylpyrrolidone. (From Merck Index, 11th ed) Pyrrolidinone,Pyrrolidone,Pyrrolidones
D003600 Cytosol Intracellular fluid from the cytoplasm after removal of ORGANELLES and other insoluble cytoplasmic components. Cytosols
D005260 Female Females
D006152 Cyclic GMP Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed) Guanosine Cyclic 3',5'-Monophosphate,Guanosine Cyclic 3,5 Monophosphate,Guanosine Cyclic Monophosphate,Guanosine Cyclic-3',5'-Monophosphate,3',5'-Monophosphate, Guanosine Cyclic,Cyclic 3',5'-Monophosphate, Guanosine,Cyclic Monophosphate, Guanosine,Cyclic-3',5'-Monophosphate, Guanosine,GMP, Cyclic,Guanosine Cyclic 3',5' Monophosphate,Monophosphate, Guanosine Cyclic

Related Publications

A C Okogbule-Wonodi, and B O Ibe, and B W Yue, and S Hsu, and J U Raj
July 1996, Respiration physiology,
A C Okogbule-Wonodi, and B O Ibe, and B W Yue, and S Hsu, and J U Raj
August 1981, British journal of pharmacology,
A C Okogbule-Wonodi, and B O Ibe, and B W Yue, and S Hsu, and J U Raj
February 1981, Canadian journal of physiology and pharmacology,
A C Okogbule-Wonodi, and B O Ibe, and B W Yue, and S Hsu, and J U Raj
November 1964, Journal of applied physiology,
A C Okogbule-Wonodi, and B O Ibe, and B W Yue, and S Hsu, and J U Raj
July 1992, The American journal of physiology,
A C Okogbule-Wonodi, and B O Ibe, and B W Yue, and S Hsu, and J U Raj
November 1999, The American journal of physiology,
A C Okogbule-Wonodi, and B O Ibe, and B W Yue, and S Hsu, and J U Raj
December 1991, Pediatric research,
A C Okogbule-Wonodi, and B O Ibe, and B W Yue, and S Hsu, and J U Raj
July 2005, American journal of physiology. Lung cellular and molecular physiology,
A C Okogbule-Wonodi, and B O Ibe, and B W Yue, and S Hsu, and J U Raj
June 1970, Human pathology,
A C Okogbule-Wonodi, and B O Ibe, and B W Yue, and S Hsu, and J U Raj
July 1997, British journal of pharmacology,
Copied contents to your clipboard!